drugset / Trial / NCT04513925
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Timeline
- Start
- 2020-08-24
- Primary completion
- 2025-05-27
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1680 mg | Intravenous |
| Comparator | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 840 mg | Intravenous |